Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Acta Haematol
; 145(6): 642-649, 2022.
Article
en En
| MEDLINE
| ID: mdl-35933982
ABSTRACT
INTRODUCTION:
Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions.METHODS:
Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up.RESULTS:
A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment.CONCLUSION:
We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Subunidad alfa 2 del Factor de Unión al Sitio Principal
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Acta Haematol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Israel